ReviewJournal of clinical medicine2024
The Recent Management of Vestibular Schwannoma Radiotherapy: A Narrative Review of the Literature.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Transcriptomic meta-analysis identifies dysregulated pathways and potential therapeutic targets in Vestibular Schwannoma.PloS one · 2026Pooled it
- Treatment strategies and survival outcomes of vestibular schwannoma: a comparative study based on Surveillance, Epidemiology, and End Results (SEER) database.Translational cancer research · 2026Article
- Radiotherapy for Vestibular Schwannoma: Retrospective Cohort and Propensity Score Matching Analysis.Journal of neurological surgery. Part B, Skull base · 2026Article
- Article
- Volumetric and Linear Imaging Response After Stereotactic Radiotherapy for Vestibular Schwannoma.Cureus · 2025Article
- Global Growth and Distribution of CyberKnife Stereotactic Radiosurgery: A Bibliometric Analysis.Neurosurgery practice · 2025Review
- Predictors of Growth of Vestibular Schwannoma After Gamma Knife Treatment: A Systematic Review.Cancers · 2025Review
- Analysis of quality of life and outcomes of vestibular schwannoma patients after resection and radiosurgery in an interdisciplinary treatment concept.Scientific reports · 2025Article
- Recurrent Ulnar Nerve Schwannoma in the Cubital Tunnel Elbow: A Rare Presentation and Surgical Management.Cureus · 2024Article
- Combined subtotal resection and stereotactic radiosurgery for large vestibular schwannomas: A systematic review and meta-analysis.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) plays an important role in the therapeutic management of vestibular schwannoma (VS). Fractionated stereotactic radiotherapy (FSRT) or radiosurgery (SRS) are the two modalities available. The purpose of this article is to review the results of VS RT studies carried out over the last ten years. MATERIALS AND
methodsA literature search was performed with PubMed and Medline by using the words vestibular schwannoma, acoustic neuroma, radiotherapy, and radiosurgery.
resultsIn small (<3 cm) VS, SRS offers a local control rate of >90%, which seems similar to microsurgery, with a favorable tolerance profile. Hypofractionated FSRT (three to five fractions) is a relatively recent modality and has shown similar outcomes to normofractionated FSRT. Hearing preservation may highly differ between studies, but it is around 65% at 5 years.
conclusionsSRS and FRST are non-invasive treatment options for VS. SRS is often preferred for small lesions less than 3 cm, and FSRT for larger lesions. However, no randomized study has compared these modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.